These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11681242)

  • 21. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.
    Yamamoto N; Tsurutani J; Yoshimura N; Asai G; Moriyama A; Nakagawa K; Kudoh S; Takada M; Minato Y; Fukuoka M
    Anticancer Res; 2006; 26(1B):777-81. PubMed ID: 16739353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
    Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
    J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel pharmacokinetics, threshold models, and dosing strategies.
    Extermann M
    J Clin Oncol; 2003 Jul; 21(14):2804-5; author reply 2805-6. PubMed ID: 12860962
    [No Abstract]   [Full Text] [Related]  

  • 24. Paclitaxel pharmacokinetics, threshold models, and dosing strategies.
    Sparreboom A; Verweij J
    J Clin Oncol; 2003 Jul; 21(14):2803-4; author reply 2805-6. PubMed ID: 12860961
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy.
    Brenner B; Ilson DH; Minsky BD; Bains MS; Tong W; Gonen M; Kelsen DP
    J Clin Oncol; 2004 Jan; 22(1):45-52. PubMed ID: 14701767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer].
    Kuroi K; Tanaka C; Bando H; Saji S; Hayashi K; Toi M
    Gan To Kagaku Ryoho; 2002 Jan; 29(1):55-60. PubMed ID: 11816478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reduction of adverse reactions of anticancer agents with altered dose and schedule].
    Horikoshi N
    Nihon Rinsho; 2003 Jun; 61(6):1021-4. PubMed ID: 12806954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment with three-weekly paclitaxel of an anthracycline-refractory classical Kaposi's sarcoma.
    Silvestris N; Galetta D; Colucci G
    Anticancer Res; 2009 Feb; 29(2):675-6. PubMed ID: 19331220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A phase II study of weekly paclitaxel for advanced or recurrent breast cancer].
    Wada Y; Otoshi M; Jitsuko A; Nishikawa H; Takahara S; Tsubono M; Imai S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1041-5. PubMed ID: 17637539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Weekly paclitaxel therapy for locoregional lymph node recurrence of estrogen-receptor-negative breast cancer].
    Nishimura H; Hamanaka K; Sakai H; Ohno Y; Miyagawa Y; Seki H; Munakata Y
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):627-30. PubMed ID: 15114714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
    Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
    Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metronomic schedule of paclitaxel is effective in hormone receptor-positive and hormone receptor-negative breast cancer.
    Mehta RS; Jackson D; Schubbert T
    J Clin Oncol; 2009 Jun; 27(18):3067-8; author reply 3068-9. PubMed ID: 19451417
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
    Toppmeyer D; Seidman AD; Pollak M; Russell C; Tkaczuk K; Verma S; Overmoyer B; Garg V; Ette E; Harding MW; Demetri GD
    Clin Cancer Res; 2002 Mar; 8(3):670-8. PubMed ID: 11895894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The effect of weekly docetaxel and concurrent radiation for advanced breast cancer--case report].
    Kashiyama S; Ohnishi H; Kuriyama K; Komiyama T; Marino K; Araki T
    Gan To Kagaku Ryoho; 2005 May; 32(5):679-82. PubMed ID: 15918572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).
    Kodera Y; Ito S; Mochizuki Y; Fujitake S; Koshikawa K; Kanyama Y; Matsui T; Kojima H; Takase T; Ohashi N; Fujiwara M; Sakamoto J; Akimasa N;
    Anticancer Res; 2007; 27(4C):2667-71. PubMed ID: 17695430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stewart-Treves syndrome: questionable response to weekly paclitaxel.
    Paydas S; Yapar Z; Gonlusen G
    Chemotherapy; 2010; 56(1):66-8. PubMed ID: 20145393
    [No Abstract]   [Full Text] [Related]  

  • 39. The taxanes: dosing and scheduling considerations.
    Rowinsky EK
    Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):7-19. PubMed ID: 9110338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New approach reduces side effects of high-dose chemotherapy for breast cancer.
    Oncology (Williston Park); 1999 Sep; 13(9):1316. PubMed ID: 10509326
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.